Exploring the people, challenges, and opportunities impacting the global #medtech regulatory, reimbursement and policy communities. Likes,RTs,etc ≠ endorsement.
- Tweets3.3K
- Following142
- Followers264
- Likes8.4K
ALT #ICYMI: One overlooked difference between FDA QMSR and EU MDR could complicate your risk management strategy. The #FDA and EU MDR have different expectations for medical device risk management. See how they compare: https://bit.ly/4jvzfD9
ALT The next chapter of #medtech is already taking shape. Explore what a new administration could mean for the industry with a FREE Market Pathways feature article: https://bit.ly/4hR1ZoA
ALT The right #marketaccess strategy can make all the difference in bringing medical technologies to market. We have the tools to make it easier than ever before. Get them all here: https://bit.ly/4hV6FtA
ALT 3 areas shaping #medtech: regulation, reimbursement, and market access. Stay informed with expert insights from the Market Pathways newsletter: https://bit.ly/4dMJuiL
ALT 3 reasons to listen to the Market Pathways Podcast: • Stay ahead of #medtech policy • Hear from industry experts • Gain real-world insights Listen now: https://bit.ly/4A3yPcf
ALT 1 new EU decision marks a milestone in AI regulation. Implementing Decision (EU) 2026/2274 introduces the first harmonised #AI Act standard focused on quality management systems. Get more access to docs like this from Pathways' Document Depot: https://bit.ly/4iv111t
ALT 5 free #medtech cheat sheets covering regulatory updates, reimbursement challenges, MDUFA VI, and more. Get key takeaways from our top 2025 articles: https://bit.ly/4BfIQUV
ALT EU MDR reform is in the spotlight. 3 reasons to listen: • Understand potential changes • Hear expert insights • Stay ahead of #regulatory developments Listen here: https://bit.ly/4zmp7kK
ALT .@MedTechStrat, @Market_Pathways, and the #medtech community are already making plans for Boston. Come meet some members of our team at Booth #1136 at #MedTechCon:
ALT 1 new #FDA final order for infant monitoring #medicaldevices. The agency has codified Class II requirements for OTC pulse rate and oxygen saturation monitors. Get access to more docs like this here: https://bit.ly/4B9luR0
ALT FDA QMSR and EU MDR take different approaches to residual risk. Learn how manufacturers can align risk management across both markets. Read more: https://bit.ly/4zPQ3tx #medtech Source: FDA QMSR; EU MDR 2017/745
ALT Your free Market Pathways feature article is ready. 📖 Explore what a new administration could mean for the #medtech industry: https://bit.ly/3TrgCpj
ALT #ICYMI: There’s plenty happening across the #medtech policy landscape. Catch up on RAPID, EU Joint Clinical Assessments, MDUFA VI, NTAP updates and more in the latest Market Pathways digital edition: https://bit.ly/4yxBv13
